Who are Subcutaneous depot medroxyprogesterone acetate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natazia, Faslodex, Ortho Evra, Elocon, Gynorest, Progesterone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/subcutaneous-depot-medroxyprogesterone-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Subcutaneous depot medroxyprogesterone acetate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subcutaneous depot medroxyprogesterone acetate (Subcutaneous depot medroxyprogesterone acetate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progestin contraceptive. Area: Contraception.

marketed Progestin contraceptive Progesterone receptor Contraception Small molecule Live · refreshed every 30 min

Target snapshot

Subcutaneous depot medroxyprogesterone acetate (Subcutaneous depot medroxyprogesterone acetate) — Planned Parenthood Federation of America. Medroxyprogesterone acetate is a synthetic progestin that prevents pregnancy by suppressing ovulation and altering the uterine environment.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Subcutaneous depot medroxyprogesterone acetate TARGET	Subcutaneous depot medroxyprogesterone acetate	Planned Parenthood Federation of America	marketed	Progestin contraceptive	Progesterone receptor
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	marketed	Progestin	Progesterone receptor	2010-01-01
Faslodex	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
Ortho Evra	NORELGESTROMIN		marketed	Estrogen [EPC]	Progesterone receptor	2001-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	marketed	Corticosteroid	Progesterone receptor	1987-01-01
Gynorest	DYDROGESTERONE	Solvay	marketed	dydrogesterone	Progesterone receptor	1982-01-01
Progesterone	Progesterone plus HCG	Dunamenti REK Istenhegyi IVF Center	marketed	Progesterone [EPC]	progesterone receptor, luteinizing hormone/choriogonadotropin receptor	1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-29 — Elocon · 7544192 · Method of Use · US
2027-06-12 — Elocon · 8025635 · Formulation · US
2028-01-30 — Natazia · 8153616 · US
2031-10-03 — Elocon · 10357640 · Method of Use · US
2032-02-08 — Elocon · 8763222 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-03-13 — Elocon · 10406332 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US
2034-11-24 — Elocon · 10232152 · Formulation · US

Sponsor landscape (Progestin contraceptive class)

Pfizer · 1 drug in this class
Planned Parenthood Federation of America · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Subcutaneous depot medroxyprogesterone acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/subcutaneous-depot-medroxyprogesterone-acetate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab